retatrutide phase 3 trial dosage Lilly's shows 28% weight loss, but increased side effects New Phase 3 retatrutide data

While previous generations GLP-1 agonists (liraglutide) have led to weight loss of 5-10% in most cases, semaglutide can lead to weight loss of up to 20%

An increased concentration of cAMP leads to the activation of protein kinase A (PKA), which activates tissue-specific downstream signaling pathways ( functional antagonism of the GIP receptor ( Figure 2C )

In a 2023 Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al.), retatrutide produced 22.8% to 24.2% mean weight loss at 48 weeks at the higher doses (8 to 12 mg)

So, if they dont contain GLP-1, what are they made of

Log in Brain & Memory Vinco 60 capsules $N/A (MSRP) Create account for pricing Already have an account